

Erodible Polymer Particle Oral Vaccine Adjuvant

Tech ID: 24979 / UC Case 2015-253-0

TECHNOLOGY DESCRIPTION

Helicobacter pylori is a known cause of gastric cancer, and over half of the world's population is infected with H. pylori. According to the World Health Organization, gastric cancer caused by H. pylori is the third leading cause of cancer mortality in the world. A novel nanoparticle adjuvant preparation has been developed which combines vaccination with an agent that enhances gastric inflammation, boosts immunity and improves clearance of the H. pylori. This novel strategy has been tested in vitro and in vivo (mouse studies).

INTELLECTUAL PROPERTY INFO

A provisional patent application has been filed.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Published Application	20180153984	06/07/2018	2015-253
Patent Cooperation Treaty	Published Application	2016176558	11/03/2016	2015-253

CONTACT

University of California, San Diego
Office of Innovation and
Commercialization
innovation@ucsd.edu
tel: 858.534.5815.



OTHER INFORMATION

CATEGORIZED AS

- **Medical**
 - Delivery Systems
 - Disease: Cancer
 - Disease: Infectious
- Diseases
 - Vaccines

RELATED CASES

2015-253-0